• Home
  • >
  • Concord Drugs Ltd Financials
https://storage.googleapis.com/assets.cdp.blinkx.in/Blinkx_Website/icons/concord-drugs-ltd.png Logo

Concord Drugs Ltd Financial Statement

Concord Drugs Ltd Income Statement
Quarterly
Annual

*All values are in Rs. Cr

(Rs. CR)Dec 2023Sep 2023Jun 2023
Revenue12.627.398.79
Operating Expense12.065.857.39
Net Profit-0.240.530.49
Net Profit Margin-1.97.175.57
Earning Per Share-0.240.560.52
EBIDTA0.571.551.44
Effective Tax RateTBA16.2312.86

(Rs. Cr)

Revenue

Operating Expense

Net Profit

Net Profit Margin

Earning Per Share

EBIDTA

Effective Tax Rate

Concord Drugs Ltd Profit & Loss

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2023Mar 2022
Total Revenue Annual52.0858.96
Operating Expenses Annual47.5153.36
Operating Profit Annual4.585.69
Interest Annual1.711.68
Depreciation1.631.76
Net Profit Annual0.991.59
Tax Annual0.260.65

Particulars

Total Revenue Annual

Operating Expenses Annual

Operating Profit Annual

Interest Annual

Depreciation

Net Profit Annual

Tax Annual

Concord Drugs Ltd Cash Flow

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2023Mar 2022
Cash Flow at the Beginning0.060.04
Cash Flow from Operations1.660.77
Cash Flow from Investing-2.27-2.44
Cash Flow from Financing0.621.68
Cash Flow at the End0.080.04

Particulars

Cash Flow at the Beginning

Cash Flow from Operations

Cash Flow from Investing

Cash Flow from Financing

Cash Flow at the End

Concord Drugs Ltd Key Ratios

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2023Mar 2022
PBDIT Margin (%)8.799.65
PBIT Margin (%)5.666.67
PBT Margin (%)2.292.72
Net PROFIT Margin (%)1.732.7
Return On Networth / Equity (%)3.35.61
Return On Networth /Employed(%)6.048.36
Return On Assets (%)1.843.4
Total Debt / Equity(X)0.530.53
Asset Turnover Ratio (%)1.061.26

Particulars

PBDIT Margin (%)

PBIT Margin (%)

PBT Margin (%)

Net PROFIT Margin (%)

Return On Networth / Equity (%)

Return On Networth / Employed(%)

Return On Assets (%)

Total Debt / Equity(X)

Asset Turnover Ratio (%)

Concord Drugs Ltd Balance Sheet

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2023Mar 2022
Fixed Assets Annual12.2813.33
Total Current Assets Annual43.4641.89
Non Current Assets Annual14.7714.55
Total Shareholders Funds Annual31.728.36
Total Assets Annual58.2356.45

Particulars

Fixed Assets Annual

Total Current Assets Annual

Non Current Assets Annual

Total Shareholders Funds Annual

Total Assets Annual

Concord Drugs Ltd Earning Calls
Dec 2023
EPS beaten by 0.00 %

Open Demat Account

50years
*By signing up you agree to our terms & conditions
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O

Dividend Pages

PE Ratio

Get Your FAQs Right

As of May 20, 2024, Concord Drugs Ltd has a market capitalization of 25.57 Cr. Value Research classifies it as a Micro-Cap company.

No, Concord Drugs Ltd is not debt-free with a debt-to-equity ratio of 0.51.

In FY 2023, Concord Drugs Ltd recorded a total revenue of approximately 52.08 Cr marking a significant milestone in the company's financial performance.

Concord Drugs Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.0% and -0.1% annually, respectively..

Concord Drugs Ltd's current PE ratio is 25.83.

Concord Drugs Ltd's ROCE averaged 7.6% from the FY ending March 2022 to 2023, with a median of 7.6%. It peaked at 8.9% in March 2022, reflecting strong capital efficiency over the period..

Concord Drugs Ltd's latest EBIT is Rs. 2.96 Cr, surpassing the average EBIT of Rs. 3.45 Cr over the 5 years..